$REGN

46 stories mentioning REGNUpdated 3d ago

Every FINWIRES story that references REGN, newest first.

What are analysts saying about REGN?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on REGN?

Sector Update: Health Care Stocks Edge Lower Late Afternoon

Health care stocks were softer late Thursday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each easing about 0.1%.The iShares Biotechnology ETF (IBB) fell 1.8%.In sector news, Acting Attorney General Todd Blanche signed an order Thursday reclassifying state-licensed medical cannabis as a less-dangerous drug, the Associated Press reported, citing a statement from Blanche.In corporate news, Molina Healthcare (MOH) shares jumped more than 12% after the firm reported Q1 adjusted EPS that beat market expectations in the previous day.Grace Therapeutics (GRCE) tumbled 46% after the US Food and Drug Administration issued a complete response letter for its new drug application for GTx-104, an intravenous formulation of nimodipine for aneurysmal subarachnoid hemorrhage.Thermo Fisher Scientific (TMO) raised its full-year outlook as Q1 results came in stronger than expected, but organic growth fell short of analysts' estimates. Its shares fell 9.5%.Regeneron Pharmaceuticals (REGN) has struck a deal with the Trump administration to reduce drug costs for certain Americans and has secured approval for a gene therapy to treat a rare form of deafness, Bloomberg reported. Regeneron gained 2.5%.

$GRCE$MOH$REGN$TMO

Sectors143d ago

Sector Update: Health Care Stocks Lower in Afternoon Trading

Health care stocks declined Thursday afternoon, with the NYSE Health Care Index decreasing 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) fell 1.9%.In sector news, Acting Attorney General Todd Blanche signed an order Thursday reclassifying state-licensed medical cannabis as a less-dangerous drug, the Associated Press reported, citing a statement from Blanche.In corporate news, Thermo Fisher Scientific (TMO) raised its full-year outlook as Q1 results came in stronger than expected, but organic growth fell short of analysts' estimates. Shares fell 11%.Regeneron Pharmaceuticals (REGN) has struck an agreement with the Trump administration to reduce drug costs for certain Americans and has secured approval for a gene therapy to treat a rare form of deafness, Bloomberg reported. Regeneron shares rose 1.6%.Novo Nordisk (NVO) said a phase 3a trial of oral semaglutide in children and adolescents aged between 10 and 17 years with type-2 diabetes showed a "superior reduction" in a measure of blood sugar control over placebo. Shares were down 2.6%.

$NVO$REGN$TMO

Wire143d ago

Regeneron Says FDA Granted Accelerated Approval for Genetic Hearing Loss Therapy

Regeneron (REGN) said Thursday that the US Food and Drug Administration has granted accelerated approval for Otarmeni therapy indicated for the treatment of pediatric and adult patients with OTOF gene-related hearing loss.FDA's approval was based on the ongoing Chord trial that showed 16 of 20 participants experienced hearing improvements per pure tone audiometry assessments, while 14 out of 20 demonstrated an auditory brainstem response, according to a statement.Otarmeni's continued approval may be contingent upon verification and description of clinical benefit in the confirmatory portion of the Chord trial, Regeneron said.The company said it will provide Otarmeni at no cost to clinically eligible individuals in the US.Shares of the company were up 2% in Thursday trading.Price: $761.47, Change: $+14.89, Percent Change: +1.99%

$REGN

Wire143d ago

Market Chatter: Regeneron Reaches Drug Pricing Deal, Gains US Nod for Rare Deafness Therapy

Regeneron Pharmaceuticals (REGN) has struck an agreement with the Trump administration to reduce drug costs for certain Americans and has secured approval for a gene therapy to treat a rare form of deafness, Bloomberg reported on Thursday, citing a person familiar with the matter.Regeneron was the last company asked by Trump to align US costs with those in other developed countries under a most favored nations policy.The administration has pressured major pharmaceutical firms to sign pricing agreements to offer discounted prices or align costs with international markets, in exchange for incentives such as tariff exemptions.According to the report, the Food and Drug Administration is expected to authorize the treatment for an ultra-rare inherited hearing-loss condition caused by a genetic mutation.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $763.89, Change: $+17.31, Percent Change: +2.32%

$REGN

Wire143d ago

Street Color: Regeneron Pharmaceuticals Reaches Agreement With Trump Administration to Cut Drug Prices, Bloomberg Reports

$REGN

Sectors153d ago

Sector Update: Health Care Stocks Mixed Pre-Bell Monday

Health care stocks were mixed pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.5% lower and the iShares Biotechnology ETF (IBB) up 0.4%Spyre Therapeutics (SYRE) shares were up more than 29% after the company said its SPY001 investigational treatment for moderate-to-severely active ulcerative colitis met its primary and key secondary endpoints in a phase 2 trial.IDEAYA Biosciences (IDYA) stock was up more than 5% after the company said its phase 2/3 registrational trial evaluating darovasertib in combination with crizotinib in patients with metastatic uveal melanoma met its primary endpoint.Regeneron Pharmaceuticals (REGN) and Telix Pharmaceuticals (TLX) said they will jointly develop and commercialize next-generation radiopharmaceutical therapies. Telix Pharmaceuticals shares were up more than 5% premarket.

$IBB$IDYA$REGN$SYRE$TLX$XLV

Showing 41-46 of 46

Track with the FINWIRES app suite

FolioX

Track REGN in your portfolio

WheelAI

Analyze REGN options with the wheel strategy

StockInsider

See market sentiment on REGN